The study will include approximately 280 adult and adolescent participants (≥ 12 years of age) with SCD.~Eligible participants will be administered inclacumab or placebo intravenous (IV) as a single dose.~Participants that complete the study through Day 90 will be provided the opportunity to enroll in an open-label extension (OLE) study.
This Phase 3 study will assess the safety and efficacy of a single dose of inclacumab, a P-selectin inhibitor, for a vaso-occlusive crisis (VOC) after an index VOC in participants with sickle cell disease (SCD). Participants will be randomized to receive either inclacumab or placebo.